4.7 Review

MicroRNA in multiple sclerosis

Journal

CLINICA CHIMICA ACTA
Volume 516, Issue -, Pages 92-99

Publisher

ELSEVIER
DOI: 10.1016/j.cca.2021.01.020

Keywords

microRNA; Multiple sclerosis; Autoimmunity; Immune cells; Biomarkers

Funding

  1. Liaoning Province 2018 Key R&D Plan Guidance Plan Project [2018225002]

Ask authors/readers for more resources

Multiple sclerosis is an autoimmune disease affecting the CNS, with miRNAs playing a key role in its pathogenesis. MiRNAs have emerged as potential new biomarkers and therapeutic targets for MS. They show high specificity and stability in peripheral body fluids, presenting promising applications in the diagnosis and treatment of MS.
Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system (CNS). Despite a complex pathogenesis, it appears that an imbalanced immune system plays an important role in the disease process. MicroRNAs (miRNAs) are comprised of short non-coding single-stranded molecules mainly involved in regulating gene expression through the inhibition of transcription and translation. miRNAs are key regulatory molecules in the nucleus and participate in the proliferation, differentiation, and apoptosis of various cells throughout the body. Recent studies, however, have found that miRNAs are also involved in MS pathogenesis, mainly affecting glial cells and peripheral immune cells. Fortunately, miRNAs are highly stable and have high specificity in peripheral body fluids. Accordingly, these molecules have become new diagnostic and therapeutic targets. The present review discusses the role of miRNAs in the pathogenesis of MS. We highlight the potential of miRNAs as new biomarkers of MS and potential therapeutic agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available